business
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Key takeaways
- ARWR's ARO-INHBE nearly doubled tirzepatide's weight loss in combination, but its $11 billion market cap makes an outright acquisition unlikely.
- Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Cytokinetics didn't make the cut.
- AbbVie's (NASDAQ: ABBV) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.
ARWR's ARO-INHBE nearly doubled tirzepatide's weight loss in combination, but its $11 billion market cap makes an outright acquisition unlikely.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Cytokinetics didn't make the cut. Grab the names FREE today.
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets. Patent cliffs approach, GLP-1 franchises crowd in, and cardio and endocrine portfolios at majors look thin. That backdrop puts a handful of under-followed biotech names squarely in the crosshairs.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop